Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [ 18F] 3́-deoxy-3́- fluorothymidine PET: A pilot study

Biomarkers in Medicine

Volumn 6, Issue 2, 2012, Pages 231-233

  Contractor, Kaiyumars ^a   Aboagye, Eric O ^a   Jacob, Jimmy ^a   Challapalli, Amarnath ^a   Coombes, R Charles ^a   Stebbing, Justin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

biomarkers; breast cancer; circulating tumor cell; FLT; PET scanning; response

Indexed keywords

3' FLUOROTHYMIDINE F 18; DOCETAXEL;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CORRELATION ANALYSIS; HUMAN; IMAGE RECONSTRUCTION; PATIENT MONITORING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DRUG MONITORING; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; TAXOIDS;

EID: 84859068754     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.11     Document Type: Article

References (10)

1. Kenny LM, Vigushin DM, Al-Nahhas A et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F] fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 65(21), 10104-10112 (2005).
2. Soloviev D, Lewis D, Honess D, Aboagye E. [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur. J. Cancer 48(4), 416-424 (2011).
3. Contractor KB, Kenny LM, Stebbing J et al. [18F]-3'deoxy-3'- fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin. Cancer Res. 17(24), 7664-7672 (2011).
4. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, future and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
5. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(21), 4808 (2005).
6. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403 (2006).
7. Stebbing J, Jiao LR. Circulating tumour cells as more than prognostic markers. Lancet Oncol. 10(12), 1138-1139 (2009).
8. Kenny LM, Contractor KB, Stebbing J et al. Altered tissue 3'-deoxy-3'-[18F] fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin. Cancer Res. 15(21), 6649-6657 (2009).
9. Contractor KB, Kenny LM, Stebbing J et al. Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography. Nucl. Med. Commun. 32(11), 997-1004 (2011).
10. Jiao LR, Apostolopoulos C, Jacob J et al. Unique localization of circulating tumor cells in patients with hepatic metastases. J. Clin. Oncol. 27, 6160-6165 (2009)